When to go up a dose on tirzepatide: what actually drives the decision

The myth: you move up automatically every four weeks

A lot of people starting tirzepatide assume the schedule is mechanical, four weeks at 2.5 mg, then four weeks at 5 mg, and so on, almost like ticking boxes off a list. That picture is understandable, because the licensed titration schedule does use four-week intervals as a minimum. But the word minimum matters enormously, and it is the part most accounts leave out.

The starting dose exists primarily to reduce the nausea, diarrhoea and fatigue that many people notice when a GLP-1 medicine is introduced. It is a period of adjustment, not a therapeutic plateau you need to escape as quickly as possible. Moving up before that adjustment is complete tends to make side effects worse, which can lead people to stop treatment altogether, the opposite of the goal.

In practice, a prescriber reviewing your progress will want to know whether gastrointestinal symptoms have calmed down, whether you are managing food and fluids normally, and whether there are any new concerns. All of those things take precedence over the date on the calendar. The full picture of how tirzepatide's dose range is structured makes clear that the schedule is a framework, not a timetable.

Staying at 2.5 mg for eight weeks rather than four is not unusual. It means your prescriber is being careful. That is exactly what careful looks like.

What the prescriber is actually looking for before recommending a step up

When a clinical review takes place before a repeat prescription, the prescriber is working through a practical checklist. Side effects are central to it. Nausea and loose stools that have not settled, or symptoms severe enough to affect daily life, are a signal to hold the current dose rather than increase it. The NHS medicines guidance for tirzepatide makes clear that tolerability is the primary lens through which dose progression is assessed.

Beyond side effects, the prescriber will consider whether you are eating and drinking adequately. Dehydration from persistent vomiting or diarrhoea is a real concern with any GLP-1 medicine, and it would be clinically irresponsible to add further appetite suppression on top of it. They will also look at how weight is responding, though the absence of dramatic early loss is not, by itself, a reason to rush upward, some people respond most strongly at higher doses.

For people transferring their prescription or requesting a dose increase with a new provider, evidence of the current dose and any recent clinical notes will typically be required. At nume, our clinical team reviews each case individually before authorising any increase, a real clinician reads the submission, not automated software. There is also a practical note about oral contraceptives: for the first four weeks of treatment and for four weeks after each dose increase, women taking the pill should use an additional non-oral method of contraception, because tirzepatide may reduce pill absorption. NHS England's guidance on weight-management injections covers this clearly.

One question our prescribers hear regularly: does weight loss slow down between doses? Sometimes. If you are unsure when to up your Mounjaro dose, it helps to know that a temporary plateau at a given dose does not always mean it is time to go higher. It can mean the body is recalibrating. Patience at this stage saves a lot of frustration later.

Which doses exist and where most people find their maintenance level

Tirzepatide is available in the UK at six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each is delivered via the same pre-filled KwikPen. The 2.5 mg pen is the starting point; 15 mg is the highest licensed dose. In the SURMOUNT-1 trial, participants at the 15 mg dose saw an average body-weight reduction of around 20 to 21 per cent over 72 weeks, figures published in the New England Journal of Medicine and referenced in NICE's appraisal of tirzepatide (TA1026).

Most people do not need to reach 15 mg to see meaningful results. The right maintenance dose is the lowest dose at which you are losing weight steadily and tolerating treatment well. Understanding when to go up to 5 mg on Mounjaro is a good place to start, since that first step up sets the pattern for how progression is managed throughout treatment. There is no hierarchy of success based on which pen you end up on.

If you are currently managing your treatment through another provider and considering a change, the route to a private prescription always involves a clinical review, the dose you are on now does not transfer automatically, and nor should it. For a broader sense of how tirzepatide works as a weight-loss medicine, our main Mounjaro page covers the mechanism, eligibility and what to expect in the first weeks.

One thing worth keeping in mind: the cost of treatment varies by dose, since higher doses use higher-strength pens. If you are thinking about the financial side alongside the clinical picture, it is worth reviewing what is included in a full treatment plan before making any decisions.

What to do if you feel ready to increase but your prescriber says wait

It can be genuinely frustrating to feel as though progress has stalled while staying at the same dose. That frustration is understandable, and it is worth saying clearly: wanting to move forward is not impatience, it is a reasonable response to having started treatment with a goal in mind.

The most useful thing in that situation is a direct conversation with your prescriber rather than taking matters into your own hands, and our guide on when you go up a dose on Mounjaro explains the clinical factors that typically inform that decision. Splitting doses, skipping doses, or sourcing a higher strength from an unverified seller are all approaches that carry real clinical risk. Counterfeit pens sold through unregulated channels have reached the UK market, the MHRA has documented seizures of fake tirzepatide pens and issued guidance on reporting suspect sellers via Yellow Card. The risk is not abstract.

If a review is overdue or you have concerns, the right step is to contact your provider's aftercare team. At nume, that support runs seven days a week. A good prescriber will not leave you stuck at a dose indefinitely without a reason; equally, a good patient-prescriber relationship means the clinical call belongs to the clinician. The frequently asked questions on our site cover many of the practical points people raise between appointments, and the contact page is there for anything that falls outside them.

Ready to talk through where you are in your treatment? Check your eligibility and let our prescribers review your situation properly.